Form 4: 4D Molecular Therapeutics CEO David Kirn Reports Stock Transactions
SEC Form 4 Filing
CEO David Kirn of 4D Molecular Therapeutics reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.
Summary
- David Kirn, CEO of 4D Molecular Therapeutics, reported transactions involving the company's common stock on July 10, 2024.
- Kirn exercised stock options to acquire 11,653 shares at $14.42 and 1,270 shares at $15.78.
- He then sold 12,923 shares at a weighted average price of $22.4869.
- These transactions were executed under a 10b5-1 trading plan adopted on March 21, 2024.
- Following these transactions, Kirn beneficially owns 1,059,153 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. The CEO is selling a small portion of their holdings.
Positives
- The CEO's transactions are being conducted under a pre-arranged 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.
Negatives
- The sale of shares by the CEO, even under a 10b5-1 plan, could be perceived negatively by some investors.
Risks
- The market's reaction to the CEO's stock sales could put downward pressure on the stock price.
Industry Context
Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's stock.
Stakeholder Impact
- Shareholders may react to the CEO's stock sales, potentially influencing the stock price.
Key Dates
| Date | Description |
|---|---|
| February 1, 2022 | Vesting Commencement Date for some stock options. |
| December 11, 2023 | Vesting Commencement Date for some stock options. |
| March 21, 2024 | Date the 10b5-1 trading plan was adopted. |
| July 10, 2024 | Date of the reported transactions. |
| July 12, 2024 | Date of the signature on the form. |
| December 10, 2033 | Expiration date for some stock options. |
| January 31, 2032 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.